Publication: 859

Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor–Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype—ACOSOG Z1031
      QxMD      Google Scholar   
Citation:
J Clin Oncol vol 29 (17) 2342-2349
Year:
2011
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pmc-release
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
Parents:
425   528   784  
Children:
None
Program:
OGC
Primary Committee:
Breast
Sec. Committees:
   
Pharmas:
 
Grants:
R01 CA095614, R01 CA095614-09, R01-CA095614, U01-CA114722, U10-CA076001, U24-CA114736  
Corr. Author:
 
Authors:
                                         
Networks:
 
Study
ACOSOG-Z1031
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
3
Keywords: